Bali

Bali Bio is a preclinical-stage biotechnology company focused on the discovery and development of novel biologics for the treatment of cancer and autoimmune diseases. The company utilizes a proprietary protein engineering platform to design multi-specific antibodies that target complex disease pathways with high precision. Their primary research focus involves targeting the B-cell activating factor receptor (BAFF-R) and other key signaling pathways in B-cell malignancies and inflammatory conditions. Headquartered in San Francisco, Bali Bio aims to translate structural biology insights into transformative medicines for patients with limited therapeutic options. The firm is supported by prominent life science investors and maintains a robust pipeline of early-stage candidates.